The images showed that nearly all the antibodies bind to a single domain of the receptor, providing a viable target for novel therapeutics.

In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications.

SHERLOCK, a rapid CRISPR-based diagnostic, detects Candida auris and antifungal resistance mutations in patient samples in under an hour.

Benefits seen from embracing platform technologies, combined with the role such systems played during the pandemic, are key dynamics.

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Avenue Biosciences technology collects data sets on how specific signal peptides impact specific protein targets.

The integration of flexible manufacturing, process intensification, and sustainability is redefining the global supply chain.

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for biopharma. From digital transformation to an AI revolution to more ...

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...

Silicon Valley microprocessing giant Nvidia and pharma powerhouse Eli Lilly announced a five-year, $1 billion partnership to create a “Co-Innovation AI Lab” designed to address key challenges in AI ...

Nick Edwards, PhD, CEO of Potato, has a “burning desire” to speed up scientific discovery. In an interview with GEN, he explained how Potato’s AI “scientist,” named Tater, recently replicated a main ...

Researchers say the living sensor display technology may have potential applications beyond human healthcare, in veterinary ...